Previous close | 300.60 |
Open | 302.10 |
Bid | 295.05 x 0 |
Ask | 0.00 x 0 |
Day's range | 292.20 - 308.00 |
52-week range | 217.50 - 315.00 |
Volume | |
Avg. volume | 8,242,529 |
Market cap | 354.526B |
Beta (5Y monthly) | 0.42 |
PE ratio (TTM) | 29.39 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.50 (0.50%) |
Ex-dividend date | 07 Jul 2023 |
1y target est | N/A |
Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase.
Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India. Biocon Biologics personnel working at the insulin devices manufacturing facility in Bengaluru, India. BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’ biosimilars business in 31 European countries has been successfully completed. Following the acquisitio